Advancing First-in-Class TIL Programs Through Uncertain Regulatory & Quality Expectations for Successful Approvals

• Navigating first time interactions with inexperienced review teams
• Defining and defending potency assays for complex cell products
• Applying quality by design concepts to highly variable therapies

Speakers:

Parameswaran Hari

Chief Development Officer

Obsidian Therapeutics